#AAN2018 – Rituxan a Promising First-line Immunotherapy in Late-onset MG, Study Suggests – Myasthenia Gravis News
Myasthenia Gravis News |
#AAN2018 – Rituxan a Promising First-line Immunotherapy in Late-onset MG, Study Suggests
Myasthenia Gravis News The researchers analyzed Rituxan's effectiveness and safety by treating six late-onset MG patients (five women and one man) with the therapy, ultimately evaluating its potential as a first-line immunotherapy. Mean age of myasthenia gravis onset was 66 … |
